Publisert 22.06.2016

Regenics AS Annual Report 2016

Regenics post a positive 2016 result with topline of 0.35 mill NOK. 

Regenics post a positive annual result with topline 0.35 mill NOK. surplus. Progress on the wound healing medical device programm continued in 2016. Launch of LEX ingredient to US (Sapelo) and important collaboratve R&D agreements where highlights. Post reporting Regenics AS obtaines UE Horizon 2020 "Seal of Excellence" for its new indication psoriasis and general validation of innovation, excellence and performance" (see more on EU Horizon 2020 "Seal of Excellence")

Annual Report 2016 (password)

 

 

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.